Evidence map›Paper›PMID 41894511›Full record

ArticleScience advances2026

Cold atmospheric plasma-engineered nanovaccine with spatiotemporal sequential immunization reprograms antitumor immunity.

Shuo Li, Peiyu Wang, Zhenyu Wu, Qianwen Mu, Renwu Zhou, Nina Liu, Yue Xi, Xiaoyu An, Yan Li, Di Sun and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Shuo LiState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.ORCID 0009-0007-0527-2792
Peiyu WangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Fujian Engineering Research Center of Molecular Theranostic Technology, School of Public Health, Xiamen University, Xiamen 361102, China.ORCID 0000-0002-6455-5043
Zhenyu WuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.ORCID 0009-0003-1949-280X
Qianwen MuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.ORCID 0009-0001-3693-3262
Renwu ZhouState Key Laboratory of Electrical Insulation and Power Equipment, Centre for Plasma Biomedicine, School of Electrical Engineering, Xi'an Jiaotong University, Xi'an 710049, China.ORCID 0000-0003-1773-7095
Nina LiuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.
Yue XiState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.
Xiaoyu AnState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.ORCID 0009-0004-5975-0727
Yan LiState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Fujian Engineering Research Center of Molecular Theranostic Technology, School of Public Health, Xiamen University, Xiamen 361102, China.ORCID 0000-0003-3020-6424
Di SunState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.
Hao LiangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.
Chenhao ZhangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Fujian Engineering Research Center of Molecular Theranostic Technology, School of Public Health, Xiamen University, Xiamen 361102, China.
Qihang HuangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.
Ziqi ZhuangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Fujian Engineering Research Center of Molecular Theranostic Technology, School of Public Health, Xiamen University, Xiamen 361102, China.ORCID 0009-0007-2144-6182
Xiaojun WangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.
Liqian ZhaoInstitute of Translational Medicine, School of Medicine, Zhejiang University, Hangzhou 310000, China.ORCID 0000-0001-5068-3688
Dingwei GanState Key Laboratory of Electrical Insulation and Power Equipment, Centre for Plasma Biomedicine, School of Electrical Engineering, Xi'an Jiaotong University, Xi'an 710049, China.ORCID 0000-0002-4257-2213
Xiaoyong WangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Fujian Engineering Research Center of Molecular Theranostic Technology, School of Public Health, Xiamen University, Xiamen 361102, China.ORCID 0000-0001-6048-6100
Xue LiuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Fujian Engineering Research Center of Molecular Theranostic Technology, School of Public Health, Xiamen University, Xiamen 361102, China.
Gang LiuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Fujian Engineering Research Center of Molecular Theranostic Technology, School of Public Health, Xiamen University, Xiamen 361102, China.ORCID 0000-0003-2613-7286
Chao LiuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, and Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China.ORCID 0000-0003-1951-2375

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer immunotherapy remains limited by insufficient antigen presentation and immunosuppressive tumor microenvironment. Here, we present a vaccine strategy based on cold atmospheric plasma (CAP)-engineered tumor cell-derived immune reprogramming nanovesicles (CAPTURE) that integrates spatiotemporal sequential immunization to potentiate antitumor immunity. CAPTURE is engineered from tumor cells pretreated with CAP, which up-regulates major histocompatibility complex class I expression via p62-mediated autophagy to promote full-spectrum epitope antigen presentation, and surface-functionalized anti-CD28 (αCD28) on CAPTURE provides costimulatory signals to directly activate T cells through αCD28-CD28, bypassing B7-CTLA-4-mediated T cell inhibition. Under spatiotemporal sequential immunity, CAPTURE exhibits homologous tumor targeting and lymph node accumulation, enhancing antigen presentation for CD8

Indexed as

Cancer VaccinesNanovaccinesNeoplasmsPlasma GasesAnimalsAntigen PresentationCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansImmunizationMiceTumor MicroenvironmentCancer VaccinesNanovaccinesPlasma Gases

Identifiers

PMID41894511
PMCPMC13025033

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.